Treatment with recombinant IL-22 has no effect on acute GvHD (day 7) but reduces severity of chronic GvHD (day 60), which is associated with increased numbers of natural Tregs in the thymus and the spleen and decreased numbers of Th1 cells in the spleen. Here, IL22 is linked to graft versus host disease.